Last 12 months
Inside the activity.
0 purchase rows · 12 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 5 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 18, 2022 Filed Apr 19, 2022 23:18 UTC |
Barrow RobertDirector · Chief Executive Officer
|
Tax withholdingSubordinate Voting Shares | 19,110 | $0.92 | $17,581.20 |
DisclosureSEC source: 0001209191-22-024842 · doc4.xml · nonDerivative · entry 1 Barrow Robert · CIK 0001897557 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,014,257 F1 · kind: The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the non-reportable vesting and settlement of 40,312 restricted stock units. F2 · price: The closing price of our Subordinate Voting Shares as of April 18, 2022 on the NEO was $1.16 Canadian Dollars. This represents the price in United States Dollars. Read SEC document |
| March 28, 2022 Filed Mar 30, 2022 01:39 UTC |
Karlin DanielChief Medical Officer
|
Tax withholdingSubordinate Voting Shares | 10,203 | $1.17 | $11,937.51 |
DisclosureSEC source: 0001209191-22-021558 · doc4.xml · nonDerivative · entry 1 Karlin Dan · CIK 0001897618 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,108,554 F1 · kind: The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the non-reportable vesting and settlement of 23,541 restricted stock units ("RSUs"). F2 · price: The closing price of our Subordinate Voting Shares as of March 28, 2022 on the NEO was $1.46 Canadian Dollars. This represents the price in United States Dollars. Read SEC document |
| March 24, 2022 Filed Mar 29, 2022 00:30 UTC |
Hu Cynthia W.Chief Legal Officer&Secretary
|
GrantStock Option (Right to Buy) · Derivative | 1,560,000 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0001209191-22-021393 · doc4.xml · derivative · entry 2 Hu Cynthia W. · CIK 0001364709 · Chief Legal Officer&Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,560,000 Underlying: Subordinate Voting Shares · 1,560,000 shares Expires 2027-03-23 F2 · derivative.exercise_price: The option grant has an exercise price of $1.48 Canadian Dollars. This represents the exercise price in United States Dollars. F3 · derivative.exercise_date: 25% of the shares underlying the option shall vest and become exercisable on December 6, 2022; the remaining shares underlying the option shall vest and become exercisable with 1/48th of the total shares vesting at the end of each month thereafter for the succeeding 36 months, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date. Read SEC document |
| March 24, 2022 Filed Mar 29, 2022 00:30 UTC |
Hu Cynthia W.Chief Legal Officer&Secretary
|
GrantSubordinate Voting Shares | 1,200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-021393 · doc4.xml · nonDerivative · entry 1 Hu Cynthia W. · CIK 0001364709 · Chief Legal Officer&Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,200,000 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one subordinate voting share of the Issuer. Of these RSUs, 25% shall vest on December 6, 2022, with 1/48th vesting at the end of each month thereafter for the succeeding 36 months, subject, to the Reporting Person providing continuous service to the Issuer on each such vesting date. Read SEC document |
| March 24, 2022 Filed Mar 29, 2022 00:24 UTC |
Halperin Wernli MiriDirector · Executive President
|
GrantStock Option (Right to Buy) · Derivative | 780,000 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0001209191-22-021391 · doc4.xml · derivative · entry 2 Wernli Miri Halperin · CIK 0001897615 · Director · Executive President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,462,500 Underlying: Subordinate Voting Shares · 780,000 shares Expires 2022-03-23 F2 · derivative.exercise_price: The option grant has an exercise price of $1.48 Canadian Dollars. This represents the exercise price in United States Dollars. F3 · derivative.exercise_date: The shares subject to the option vest and become exercisable with 1/48th of the total shares vesting monthly over 48 months from the vesting commencement date, March 24, 2022, subject to the Reporting Person providing continuous service to the Issuer as of each such vesting date. Read SEC document |
| March 24, 2022 Filed Mar 29, 2022 00:24 UTC |
Halperin Wernli MiriDirector · Executive President
|
GrantSubordinate Voting Shares | 600,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-021391 · doc4.xml · nonDerivative · entry 1 Wernli Miri Halperin · CIK 0001897615 · Director · Executive President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,275,000 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one subordinate voting share of the Issuer. The RSUs vest in 48 equal monthly installments beginning on April 24, 2022, subject, to the Reporting Person providing continuous service to the Issuer on each such vesting date. Read SEC document |
| March 24, 2022 Filed Mar 29, 2022 00:03 UTC |
Barrow RobertDirector · Chief Executive Officer
|
GrantStock Option (Right to Buy) · Derivative | 2,910,000 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0001209191-22-021385 · doc4.xml · derivative · entry 2 Barrow Robert · CIK 0001897557 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,425,500 Underlying: Subordinate Voting Shares · 2,910,000 shares Expires 2027-03-23 F2 · derivative.exercise_price: The option grant has an exercise price of $1.48 Canadian Dollars. This represents the exercise price in United States Dollars. F3 · derivative.exercise_date: The shares subject to the option vest and become exercisable with 1/48th of the total shares vesting monthly over 48 months from the vesting commencement date, March 24, 2022, subject to the Reporting Person providing continuous service to the Issuer as of each such vesting date. Read SEC document |
| March 24, 2022 Filed Mar 29, 2022 00:03 UTC |
Barrow RobertDirector · Chief Executive Officer
|
GrantSubordinate Voting Shares | 1,820,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-021385 · doc4.xml · nonDerivative · entry 1 Barrow Robert · CIK 0001897557 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,033,367 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one subordinate voting share of the Issuer. The RSUs vest in 48 equal monthly installments beginning on April 24, 2022, subject, to the Reporting Person providing continuous service to the Issuer on each such vesting date. Read SEC document |
| March 24, 2022 Filed Mar 29, 2022 00:11 UTC |
Karlin DanielChief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 1,250,000 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0001209191-22-021387 · doc4.xml · derivative · entry 2 Karlin Dan · CIK 0001897618 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,719,000 Underlying: Subordinate Voting Shares · 1,250,000 shares Expires 2027-03-23 F2 · derivative.exercise_price: The option grant has an exercise price of $1.48 Canadian Dollars. This represents the exercise price in United States Dollars. F3 · derivative.exercise_date: The shares subject to the option vest and become exercisable with 1/48th of the total shares vesting monthly over 48 months from the vesting commencement date, March 24, 2022, subject to the Reporting Person providing continuous service to the Issuer as of each such vesting date. Read SEC document |
| March 24, 2022 Filed Mar 29, 2022 00:11 UTC |
Karlin DanielChief Medical Officer
|
GrantSubordinate Voting Shares | 950,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-021387 · doc4.xml · nonDerivative · entry 1 Karlin Dan · CIK 0001897618 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,118,757 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one subordinate voting share of the Issuer. The RSUs vest in 48 equal monthly installments beginning on April 24, 2022, subject, to the Reporting Person providing continuous service to the Issuer on each such vesting date. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 23:26 UTC |
Barrow RobertDirector · Chief Executive Officer
|
Tax withholdingSubordinate Voting Shares | 12,612 | $1.00 | $12,612.00 |
DisclosureSEC source: 0001209191-22-019815 · doc4.xml · nonDerivative · entry 1 Barrow Robert · CIK 0001897557 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,213,367 F1 · kind: The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the non-reportable vesting and settlement of 40,312 restricted stock units. F2 · price: The closing price of our Subordinate Voting Shares as of March 15, 2022 on the NEO was $1.28 Canadian Dollars. This represents the price in United States Dollars. Read SEC document |
| February 26, 2022 Filed Mar 1, 2022 23:32 UTC |
Karlin DanielChief Medical Officer
|
Tax withholdingSubordinate Voting Shares | 118,143 | $1.21 | $142,953.03 |
DisclosureSEC source: 0001209191-22-014338 · doc4.xml · nonDerivative · entry 1 Karlin Dan · CIK 0001897618 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,168,757 F1 · kind: The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the non-reportable vesting and settlement of 282,500 restricted stock units. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 02:16 UTC |
Barrow RobertDirector · Chief Executive Officer
|
Tax withholdingSubordinate Voting Shares | 18,734 | $1.35 | $25,290.90 |
DisclosureSEC source: 0001209191-22-011077 · doc4.xml · nonDerivative · entry 1 Barrow Robert · CIK 0001897557 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,225,979 F1 · kind: The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the non-reportable vesting and settlement of 40,313 restricted stock units. Read SEC document |
| February 10, 2022 Filed Mar 14, 2022 22:12 UTC |
Liao CarrieVP, Controller&Acct Principal
|
GrantStock Option (Right to Buy) · Derivative | 524,450 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001209191-22-018614 · doc4.xml · derivative · entry 2 Liao Carrie · CIK 0001899817 · VP, Controller&Acct Principal 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 524,450 Underlying: Subordinate Voting Shares · 524,450 shares Expires 2027-02-09 F2 · derivative.exercise_price: The option grant has an exercise price of $1.71 Canadian Dollars. This represents the exercise price in United States Dollars. F3 · derivative.exercise_date: 25% of the shares underlying the option shall vest and become exercisable on October 21, 2022; the remaining shares underlying the option shall vest and become exercisable with 1/48th of the total shares vesting at the end of each month thereafter for the succeeding 36 months, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date. Read SEC document |
| February 10, 2022 Filed Mar 14, 2022 22:12 UTC |
Liao CarrieVP, Controller&Acct Principal
|
GrantSubordinate Voting Shares | 403,430 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-018614 · doc4.xml · nonDerivative · entry 1 Liao Carrie · CIK 0001899817 · VP, Controller&Acct Principal 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 403,430 F1 · shares: Grant of 403,430 restricted stock units ("RSUs") on February 10, 2022. Each RSU represents a contingent right to receive one subordinate voting share of the Issuer. 25% of the RSUs will vest on October 21, 2022; the remaining RSUs granted will vest with 1/48th of the total shares vesting at the end of each month thereafter for the succeeding 36 months, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date. Read SEC document |
| January 15, 2022 Filed Jan 20, 2022 00:14 UTC |
Barrow RobertDirector · Chief Executive Officer
|
Tax withholdingSubordinate Voting Shares | 190,287 | $1.05 | $199,801.35 |
DisclosureSEC source: 0001209191-22-003854 · doc4.xml · nonDerivative · entry 1 Barrow Robert · CIK 0001897557 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,244,713 F1 · kind: The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the non-reportable vesting and settlement of 608,750 restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.